Pneumology - Original Articles Open access

Acute effect of oxygen therapy on exercise tolerance and dyspnea perception in ILD patients

Authors

Published
11 October 2021
Section
Pneumology - Original Articles
DOI
10.4081/monaldi.2021.1925

Abstract

Ambulatory oxygen therapy (AOT) is commonly prescribed in interstitial lung disease (ILD) patients, with the aim of reducing dyspnea and increasing exercise tolerance. Despite its frequent use and a reasonable physiological rationale, there is a lack of evidence supporting the effect of AOT on improving dyspnea during exercise. Moreover, dyspnea encompasses distinct sensory (intensity, quality) and affective (anxiety, fear) components with different underlying neurophysiological mechanisms. The aim of this study was to evaluate the effect of oxygen supplementation on exercise tolerance and dyspnea in ILD patients with exercise induced hypoxia (EIH). Forty-seven ILD patients performed a six-minute walk test (6MWT) on room air (RA) and with oxygen supplementation (Ox). The 6MWT distance (6MWD) was significantly greater with oxygen supplementation (RA: 242±143 m vs Ox: 345±106 m p<0,01). With oxygen supplementation, the overall dyspnea and anxiety significantly decreased both at rest [1.1±1.4 Borg Unit (BU)] vs 0.4±0.9BU, p.<0.01, and 1.1±1.6BU vs 0.5±1.3 BU, p.<0.05, respectively) and at the end of exercise (5.1±2.6 BU vs 3.7±2.5 BU, p<0.001 and 3.4 ±2.9 vs 2.5±2.8, p.<0.01, respectively) despite a greater walked distance. In ILD patients with EIH, oxygen supplementation increases the exercise tolerance and reduces overall dyspnea perception and the anxiety component of breathlessness.

Keywords

Supporting Agencies

none

References

  1. Hardinge M, Annandale J, Bourne S, et al. British Thoracic Society guidelines for home oxygen use in adults. Thorax 2015;70:i1-43. DOI: https://doi.org/10.1136/thoraxjnl-2015-206865
  2. O’Donnell DE, Ora J, Webb KA S, et al. Mechanisms of activity-related dyspnea in pulmonary diseases. Respir Physiol Neurobiol 2009;167:116–32. DOI: https://doi.org/10.1016/j.resp.2009.01.010
  3. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111–7. DOI: https://doi.org/10.1164/ajrccm.166.1.at1102
  4. Palange P, Forte S, Onorati P, et al. Ventilatory and metabolic adaptations to walking and cycling in patients with COPD. J Appl Physiol (1985) 2000;88:1715–20. DOI: https://doi.org/10.1152/jappl.2000.88.5.1715
  5. Poulain M, Durand F, Palomba B, et al. 6-minute walk testing is more sensitive than maximal incremental cycle testing for detecting oxygen desaturation in patients with COPD. Chest 2003;123:1401–7. DOI: https://doi.org/10.1378/chest.123.5.1401
  6. Bradley JM, O’Neill B. Short-term ambulatory oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005;(4):CD004356. DOI: https://doi.org/10.1002/14651858.CD004356.pub2
  7. Nishiyama O, Miyajima H, Fukai Y, et al. Effect of ambulatory oxygen on exertional dyspnea in IPF patients without resting hypoxemia. Respir Med 2013;107:1241–6. DOI: https://doi.org/10.1016/j.rmed.2013.05.015
  8. Frank RC, Hicks S, Duck AM, et al. Ambulatory oxygen in idiopathic pulmonary fibrosis: of what benefit? Eur Respir J 2012;40:269–70. DOI: https://doi.org/10.1183/09031936.00007712
  9. Visca D, Montgomery A, de Lauretis A, et al. Ambulatory oxygen in interstitial lung disease. Eur Respir J 2011;38:987–90. DOI: https://doi.org/10.1183/09031936.00190710
  10. Bell EC, Cox NS, Goh N, et al. Oxygen therapy for interstitial lung disease: a systematic review. Eur Respir Rev 2017;26:160080. DOI: https://doi.org/10.1183/16000617.0080-2016
  11. Khor YH, Renzoni EA, Visca D, et al. Oxygen therapy in COPD and interstitial lung disease: navigating the knowns and unknowns. ERJ Open Res 2019;5:00118-2019. DOI: https://doi.org/10.1183/23120541.00118-2019
  12. Parshall MB, Schwartzstein RM, Adams L, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med 2012;185:435–52. DOI: https://doi.org/10.1164/rccm.201111-2042ST
  13. Marciniuk DD, Watts RE, Gallagher CG. Dead space loading and exercise limitation in patients with interstitial lung disease. Chest 1994;105:183–9. DOI: https://doi.org/10.1378/chest.105.1.183
  14. O’Donnell DE, Chau LK, Webb KA. Qualitative aspects of exertional dyspnea in patients with interstitial lung disease. J Appl Physiol (1985) 1998;84:2000–9. DOI: https://doi.org/10.1152/jappl.1998.84.6.2000
  15. Faisal A, Alghamdi BJ, Ciavaglia CE, et al. Common mechanisms of dyspnea in chronic interstitial and obstructive lung disorders. Am J Respir Crit Care Med 2016;193:299–309. DOI: https://doi.org/10.1164/rccm.201504-0841OC
  16. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005;26:319–38. DOI: https://doi.org/10.1183/09031936.05.00034805
  17. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:5–40. DOI: https://doi.org/10.1183/09041950.005s1693
  18. Ora J, Calzetta L, Pezzuto G, et al. A 6MWT index to predict O2 flow correcting exercise induced SpO2 desaturation in ILD. Respir Med 2013;107:2014–21. DOI: https://doi.org/10.1016/j.rmed.2013.10.002
  19. Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med 1998;158:1384–7. DOI: https://doi.org/10.1164/ajrccm.158.5.9710086
  20. Stoller JK, Ferranti R, Feinstein AR. Further specification and evaluation of a new clinical index for dyspnea. Am Rev Respir Dis 1986;134:1129–34.
  21. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982;14:377–81. DOI: https://doi.org/10.1249/00005768-198205000-00012
  22. Raghu G, Rochwerg B, Zhang Y, et al. An Official ATS/ERS/JRS/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 2015;192:e3-19. DOI: https://doi.org/10.1164/rccm.201506-1063ST
  23. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932–46. DOI: https://doi.org/10.1183/09031936.04.00014304
  24. Swinburn CR, Wakefield JM, Jones PW. Relationship between ventilation and breathlessness during exercise in chronic obstructive airways disease is not altered by prevention of hypoxaemia. Clin Sci (Lond) 1984;67:515–9. DOI: https://doi.org/10.1042/cs0670515
  25. Cranston JM, Crockett A, Currow D. Oxygen therapy for dyspnoea in adults. Cochrane Database Syst Rev 2008;(3):CD004769. DOI: https://doi.org/10.1002/14651858.CD004769.pub2
  26. McKeon JL, Murree-Allen K, Saunders NA. Effects of breathing supplemental oxygen before progressive exercise in patients with chronic obstructive lung disease. Thorax 1988;43:53–6. DOI: https://doi.org/10.1136/thx.43.1.53
  27. Abernethy AP, McDonald CF, Frith PA, et al. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. Lancet 2010;376:784–93. DOI: https://doi.org/10.1016/S0140-6736(10)61115-4
  28. O’Donnell DE, D’Arsigny C, Webb KA. Effects of hyperoxia on ventilatory limitation during exercise in advanced chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:892–8. DOI: https://doi.org/10.1164/ajrccm.163.4.2007026

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

Copyright (c) 2021 The Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.